B+
Bull case
25%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
CPIX
CumberlandCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The DMD Phase 2 cardiac-function signal and planned NDA provide substantial optionality if FDA accepts the filing and ultimately finds the evidence adequate. Cumberland retained its development programs after the Apotex asset sale.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
ASSIST-SSc was too small and not powered for efficacy conclusions; gastrointestinal and bleeding-related adverse events were more frequent with ifetroban. [#PR-EARNINGS-2026-10-23]
Momentum
97
Value
48
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.25 · Bear $2.40Analysis 2026-10-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum97 · Δ7d -
Value48 · Δ7d +0.1
Sentiment46 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • ASSIST-SSc was too small and not powered for efficacy conclusions; gastrointestinal and bleeding-related adverse events were more frequent with ifetroban. [#PR-EARNINGS-2026-10-23]
- • Development-stage spending and financing needs remain difficult to assess without a current post-transaction cash-and-burn bridge. [#SEC-8K-2026-08-04]
- • FDA explicitly questioned whether the DMD package establishes substantial efficacy and previously suggested a randomized Phase 3 trial.
Catalyst clock
2027-03-31
ASSIST-SSc results reset efficacy expectations
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
48
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.2
Sentiment
46
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 97.0 / Value 48.2 / Sentiment 45.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-27. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$74.17M
Beta
-0.52
Shares Out
14.98M
P/E (TTM) · Derived
-25.9
P/S (TTM)
1.45
P/FCF (TTM)
8.97
Rev YoY
-56.3%
EPS YoY
+476.6%
Gross Margin
+72.8%
Op Margin
-29.6%
Net Debt
-$1.26M
Current Ratio
0.96
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data